Compare BIRK & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BIRK | COGT |
|---|---|---|
| Founded | 1774 | 2014 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.9B | 6.5B |
| IPO Year | 2023 | 2018 |
| Metric | BIRK | COGT |
|---|---|---|
| Price | $42.39 | $38.89 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 15 |
| Target Price | ★ $62.69 | $33.50 |
| AVG Volume (30 Days) | ★ 2.5M | 1.4M |
| Earning Date | 01-01-0001 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,871,000.00 |
| Revenue This Year | $13.71 | N/A |
| Revenue Next Year | $13.88 | $506.58 |
| P/E Ratio | $17.48 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $36.45 | $3.72 |
| 52 Week High | $57.39 | $43.73 |
| Indicator | BIRK | COGT |
|---|---|---|
| Relative Strength Index (RSI) | 59.62 | 54.34 |
| Support Level | $40.55 | $36.52 |
| Resistance Level | $44.92 | $41.31 |
| Average True Range (ATR) | 1.70 | 1.82 |
| MACD | 0.35 | 0.15 |
| Stochastic Oscillator | 95.63 | 66.97 |
Birkenstock is a German footwear brand known for comfort-focused, timeless designs, with 76% of 2022 sales coming from its top five iconic models. Products are made in Europe using sustainable, mostly locally sourced materials. The brand combines orthopedic function with everyday style, appealing to a broad audience. The Americas account for 52% of sales, EMEA 37%, with the remainder coming from Asia-Pacific, which has also the higher future growth expectations.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.